Literature DB >> 28765323

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment.

Elijah J Mun1, Hani M Babiker2, Uri Weinberg3, Eilon D Kirson3, Daniel D Von Hoff4,5.   

Abstract

Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells. TTFields target proteins crucial to the cell cycle, leading to mitotic arrest and apoptosis. TTFields also facilitate an antitumor immune response. Clinical trials of TTFields have proven safe and efficacious in patients with glioblastoma multiforme (GBM), and are FDA approved for use in newly diagnosed and recurrent GBM. Trials in other localized solid tumors are ongoing. Clin Cancer Res; 24(2); 266-75. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28765323     DOI: 10.1158/1078-0432.CCR-17-1117

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  75 in total

1.  Thermoplastic microfluidic bioreactors with integrated electrodes to study tumor treating fields on yeast cells.

Authors:  Elif Gencturk; Kutlu O Ulgen; Senol Mutlu
Journal:  Biomicrofluidics       Date:  2020-05-18       Impact factor: 2.800

Review 2.  Pharmacological properties of ginsenosides in inflammation-derived cancers.

Authors:  Do Luong Huynh; Nguyen Hoai Nguyen; Cuong Thach Nguyen
Journal:  Mol Cell Biochem       Date:  2021-04-26       Impact factor: 3.396

3.  The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3.

Authors:  Yunhui Jo; Young In Han; Eunjun Lee; Jaehyeon Seo; Geon Oh; Heehun Sung; Yongha Gi; Hyunwoo Kim; Sangmin Park; Myonggeun Yoon
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

4.  Combination therapy of Doxorubicin with TTFields and radiation: newer approaches to combat lung cancer.

Authors:  Won Seok Lee; Eun Ho Kim
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

Review 5.  Bacterial outer membrane vesicle-based cancer nanovaccines.

Authors:  Xiaoyu Gao; Qingqing Feng; Jing Wang; Xiao Zhao
Journal:  Cancer Biol Med       Date:  2022-09-23       Impact factor: 5.347

Review 6.  Tumor treating fields: a new approach to glioblastoma therapy.

Authors:  Jonathan Rick; Ankush Chandra; Manish K Aghi
Journal:  J Neurooncol       Date:  2018-01-18       Impact factor: 4.130

7.  Clinical Potential of Nerve Input to Tumors: A Bioelectricity Perspective.

Authors:  Jade A Phillips; Charlotte Hutchings; Mustafa B A Djamgoz
Journal:  Bioelectricity       Date:  2021-03-16

8.  Inhibition of Carbonic Anhydrase IX Promotes Apoptosis through Intracellular pH Level Alterations in Cervical Cancer Cells.

Authors:  Ebru Temiz; Ismail Koyuncu; Mustafa Durgun; Murat Caglayan; Ataman Gonel; Eray Metin Güler; Abdurrahim Kocyigit; Claudiu T Supuran
Journal:  Int J Mol Sci       Date:  2021-06-05       Impact factor: 5.923

Review 9.  Progress in Redirecting Antiparasitic Drugs for Cancer Treatment.

Authors:  Haoyang Huang; Qing He; Binghua Guo; Xudong Xu; Yinjuan Wu; Xuerong Li
Journal:  Drug Des Devel Ther       Date:  2021-06-22       Impact factor: 4.162

Review 10.  Epigenetically inactivated RASSF1A as a tumor biomarker.

Authors:  Dora Raos; Monika Ulamec; Ana Katusic Bojanac; Floriana Bulic-Jakus; Davor Jezek; Nino Sincic
Journal:  Bosn J Basic Med Sci       Date:  2021-08-01       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.